Citations (131)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (34)
Hiba EL Masri, Treasure M McGuire, Mieke L van Driel, Helen Benham & Samantha A Hollingworth. (2022) Dynamics of Patient-Based Benefit-Risk Assessment of Medicines in Chronic Diseases: A Systematic Review. Patient Preference and Adherence 16, pages 2609-2637.
Read now
Read now
Heather L Gelhorn, Zaneta Balantac, Christopher S Ambrose, Yen N Chung & Brian Stone. (2019) Patient and physician preferences for attributes of biologic medications for severe asthma. Patient Preference and Adherence 13, pages 1253-1268.
Read now
Read now
Tao Fan, Qiaoyi Zhang & Shuvayu S Sen. (2013) Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database. ClinicoEconomics and Outcomes Research 5, pages 589-595.
Read now
Read now
Diana Witticke, Hanna Marita Seidling, Hans-Dieter Klimm & Walter Emil Haefeli. (2012) Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics. Patient Preference and Adherence 6, pages 679-684.
Read now
Read now
V Grootaert, J De Keulenaer, S Boonen, A Sermon, I Spriet & L Willems. (2012) SELECTING AN APPROPRIATE AND REIMBURSED ANTI-OSTEOPOROTIC TREATMENT OPTION: A PRACTICAL TOOL IN THE BELGIAN SETTING. Acta Clinica Belgica 67:1, pages 13-18.
Read now
Read now
Mary K. Beard. (2012) Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference. Current Medical Research and Opinion 28:1, pages 141-147.
Read now
Read now
Raymond E. Cole. (2011) Clinical Strategies to Address Patients' Concerns in Osteoporosis Management with Bisphosphonates. Postgraduate Medicine 123:2, pages 131-144.
Read now
Read now
Véronique Rabenda & Jean-Yves Reginster. (2010) Overcoming problems with adherence to osteoporosis medication. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, pages 677-689.
Read now
Read now
Darko Kastelan, Tonko Vlak, Petar Lozo, Marina Gradiser, Sime Mijic, Tatjana Nikolic, Blazenka Miskic, Dolores Car, Gordana Tajsic, Tina Dusek, Zrinka Jajic, Frane Grubisic, Tamara Poljicanin, Miro Bakula, Fedja Dzubur, Matilda Strizak-Ujevic, Mira Kadojic, Maja Radman, Maja Vugrinec, Zeljka Kuster, Marijeta Pekez, Endi Radovic, Ljubica Labar, Zeljka Crncevic-Orlic & Mirko Korsic. (2010) Health-Related Quality of Life Among Patients with Postmenopausal Osteoporosis Treated with Weekly and Monthly Bisphosphonates. Endocrine Research 35:4, pages 165-173.
Read now
Read now
Iñaki Lete Lasa. (2010) What about compliance?. The European Journal of Contraception & Reproductive Health Care 15:4, pages 217-219.
Read now
Read now
John A. Sunyecz. (2010) Ibandronate and Nonvertebral Fracture Efficacy: Results of a Recent Pooled Analysis. The Physician and Sportsmedicine 38:2, pages 183-185.
Read now
Read now
Philip Sambrook, Ann Cranney & Jonathan D. Adachi. (2010) Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA. Current Medical Research and Opinion 26:3, pages 599-604.
Read now
Read now
Kristina Casadei & Carolyn Becker. (2009) Once-monthly risedronate for postmenopausal osteoporosis. International Journal of Women's Health 1, pages 1-9.
Read now
Read now
S. Epstein, M. Jeglitsch & E. McCloskey. (2009) Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Current Medical Research and Opinion 25:12, pages 2951-2960.
Read now
Read now
Véronique Rabenda, Michaël Hiligsmann & Jean-Yves Reginster. (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opinion on Pharmacotherapy 10:14, pages 2303-2315.
Read now
Read now
Steven Boonen. (2009) Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective. Current Medical Research and Opinion 25:10, pages 2335-2341.
Read now
Read now
Deborah T. Gold, Haian Trinh & Wael Safi. (2009) Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Current Medical Research and Opinion 25:8, pages 1831-1839.
Read now
Read now
Jean-Yves Reginster, Audrey Neuprez & Olivier Bruyère. (2008) Ibandronate in profile: drug characteristics and clinical efficacy. Expert Opinion on Drug Metabolism & Toxicology 4:7, pages 941-951.
Read now
Read now
Andrea J. Singer & Steven Boonen. (2008) Osteoporosis management: translating research into optimal fracture protection II. Current Medical Research and Opinion 24:6, pages 1789-1796.
Read now
Read now
Fernie J. A. Penning-van Beest, Joëlle A. Erkens, M. Olson & Ron M. C. Herings. (2008) Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Current Medical Research and Opinion 24:5, pages 1337-1344.
Read now
Read now
John Sunyecz. (2008) Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations. Clinical Interventions in Aging 3:4, pages 611-627.
Read now
Read now
Oliver Bock & Dieter Felsenberg. (2008) Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice. Clinical Interventions in Aging 3:2, pages 279-297.
Read now
Read now
Paul D. Miller, Sol Epstein, Farhad Sedarati & Jean-Yves Reginster. (2008) Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Current Medical Research and Opinion 24:1, pages 207-213.
Read now
Read now
E. Michael Lewiecki. (2007) Long dosing intervals in the treatment of postmenopausal osteoporosis. Current Medical Research and Opinion 23:11, pages 2617-2625.
Read now
Read now
Thomas W. Weiss, Scott C. Henderson, Colleen A. McHorney & Joyce A. Cramer. (2007) Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Current Medical Research and Opinion 23:9, pages 2193-2203.
Read now
Read now
Deborah T. Gold, Bradley C. Martin, Jennifer R. Frytak, Mayur M. Amonkar & Felicia Cosman. (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Current Medical Research and Opinion 23:3, pages 585-594.
Read now
Read now
Richard Keen, Esteban Jodar, Giovanni Iolascon, Hans-Peter Kruse, Alex Varbanov, Birgit Mann & Deborah T. Gold. (2006) European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Current Medical Research and Opinion 22:12, pages 2375-2381.
Read now
Read now
Deborah T. Gold, Wael Safi & Haian Trinh. (2006) Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Current Medical Research and Opinion 22:12, pages 2383-2391.
Read now
Read now
Laura B Hansen. (2006) Osteoporosis update: effective prevention and treatment. Expert Review of Pharmacoeconomics & Outcomes Research 6:5, pages 525-540.
Read now
Read now
C. H. A. van den Boogaard, N. S. Breekveldt‐Postma, S. E. Borggreve, W. G. Goettsch & R. M. C. Herings. (2006) Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Current Medical Research and Opinion 22:9, pages 1757-1764.
Read now
Read now
Pierre Close, Audrey Neuprez & Jean-Yves Reginster. (2006) Developments in the pharmacotherapeutic management of osteoporosis. Expert Opinion on Pharmacotherapy 7:12, pages 1603-1615.
Read now
Read now
Eamonn Brankin, Mel Walker, Niall Lynch, Terence Aspray, Yvonne Lis & Warren Cowell. (2006) The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Current Medical Research and Opinion 22:7, pages 1249-1256.
Read now
Read now
Thomas W. Weiss, Deborah T. Gold, Stuart L. Silverman & Colleen A. McHorney. (2006) An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Current Medical Research and Opinion 22:5, pages 949-960.
Read now
Read now
Jean-Yves Reginster & Véronique Rabenda. (2006) Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clinical Interventions in Aging 1:4, pages 415-423.
Read now
Read now
Articles from other publishers (97)
N.V. Grygorievа. (2021) Ефективність та безпечність ібандронової кислоти: фокус на результати рандомізованих досліджень і метааналізів. PAIN, JOINTS, SPINE 9:1, pages 36-45.
Crossref
Crossref
Dima L. Diab, Nelson B. Watts & Paul D. Miller. 2021. Marcus and Feldman's Osteoporosis. Marcus and Feldman's Osteoporosis
1721
1736
.
Deborah T. Gold. 2021. Marcus and Feldman's Osteoporosis. Marcus and Feldman's Osteoporosis
1695
1707
.
Satoshi Soen, Yuki Arai, Saori Matsuda, Kento Emori, Toshimi Ikezaki & Mitsuharu Osawa. (2020) A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis. Osteoporosis and Sarcopenia 6:4, pages 191-198.
Crossref
Crossref
T. Yoshida, H. Kinoshita, H. Taniguchi, M. Yanishi, M. Sugi & T. Matsuda. (2020) A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study. Osteoporosis International 31:7, pages 1251-1259.
Crossref
Crossref
E.V. Doskina. (2020) Treatment of patients with diabetes mellitus and postmenopausal osteoporosis — difficulties of choice. Rossiiskii vestnik akushera-ginekologa 20:6, pages 107.
Crossref
Crossref
Lei Si, Liudan Tu, Ya Xie, Andrew J. Palmer, Yuanyuan Gu, Xuqi Zheng, Jiamin Li, Qing Lv, Jun Qi, Zhiming Lin, Mingsheng Chen, Jieruo Gu & Mickaël Hiligsmann. (2019) Chinese patients’ preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment. Archives of Osteoporosis 14:1.
Crossref
Crossref
Đurđa CvjetkovićM.M., Sara Cvjetković-NedeljkovićM.M., Nikola MartićB.B., Ana SaboJ.J., Zdenko TomićS.S. & Boris MilijaševićŽ.Ž.. (2019) Analysis of utilization of bisphosphonates, strontium ranelate and denosumabe in Serbia, Finland, Norway and Denmark in the period 2013-2016. Hospital Pharmacology - International Multidisciplinary Journal 6:3, pages 857-867.
Crossref
Crossref
Maria José Fobelo Lozano & Susana Sánchez-Fidalgo. (2019) Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates. European Journal of Hospital Pharmacy 26:1, pages 4-9.
Crossref
Crossref
Stuart L. Silverman, E. Siris, D. Belazi, C. Recknor, A. Papaioannou, J. P. Brown, D. T. Gold, E. M. Lewiecki, G. Quinn, A. Balasubramanian, S. Yue, B. Stolshek & D. L. Kendler. (2018) Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. Archives of Osteoporosis 13:1.
Crossref
Crossref
Shin-ya Tamechika, Kaneshige Sasaki, Yoshihito Hayami, Shin-ichiro Ohmura, Shinji Maeda, Shiho Iwagaitsu & Taio Naniwa. (2018) Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. Archives of Osteoporosis 13:1.
Crossref
Crossref
Hiroshi Hagino, Masako Ito, Junko Hashimoto, Masao Yamamoto, Koichi Endo, Kyoko Katsumata, Yoshihiro Asao, Rumiko Matsumoto, Tetsuo Nakano, Hideki Mizunuma & Toshitaka Nakamura. (2017) Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study. Journal of Bone and Mineral Metabolism 36:3, pages 336-343.
Crossref
Crossref
G. Wang, L. Sui, P. Gai, G. Li, X. Qi & X. Jiang. (2017) The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment. Bone & Joint Research 6:7, pages 452-463.
Crossref
Crossref
Alona Eliasaf, Alina Amitai, Mira Maram Edry, Shimona Yosselson Superstine & Pnina Rotman Pikielny. (2016) Compliance, Persistence, and Preferences Regarding Osteoporosis Treatment During Active Therapy or Drug Holiday. The Journal of Clinical Pharmacology 56:11, pages 1416-1422.
Crossref
Crossref
Julia Thomson. (2016) An overview of osteoporosis. Independent Nurse 2016:17, pages 23-25.
Crossref
Crossref
Jun Iwamoto, Hiroya Okano, Takefumi Furuya, Tomohiko Urano, Masaichi Hasegawa, Hisashi Hirabayashi, Takami Kumakubo & Kazuya Makita. (2015) Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO). Journal of Bone and Mineral Metabolism 34:2, pages 201-208.
Crossref
Crossref
Deborah T. Gold. 2016. The Duration and Safety of Osteoporosis Treatment. The Duration and Safety of Osteoporosis Treatment
239
253
.
Hideaki Kishimoto & Masayuki Maehara. (2015) Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Archives of Osteoporosis 10:1.
Crossref
Crossref
T. Nakamura, M. Ito, J. Hashimoto, K. Shinomiya, Y. Asao, K. Katsumata, H. Hagino, T. Inoue, T. Nakano & H. Mizunuma. (2015) Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis. Osteoporosis International 26:11, pages 2685-2693.
Crossref
Crossref
Jun Iwamoto & Tetsuya Takada. (2015) Effect of minodronate on the speed of sound of the calcaneus in postmenopausal women with an increased risk of fractures: A clinical practice-based observational study. Journal of the Chinese Medical Association 78:10, pages 591-596.
Crossref
Crossref
Mickaël Hiligsmann, Sandrine P. G. Bours & Annelies Boonen. (2015) A Review of Patient Preferences for Osteoporosis Drug Treatment. Current Rheumatology Reports 17:9.
Crossref
Crossref
Kazuya Makita, Hiroya Okano, Takefumi Furuya, Tomohiko Urano, Hisashi Hirabayashi, Takami Kumakubo & Jun Iwamoto. (2014) Survey of the utility of once-monthly bisphosphonate treatment for improvement of medication adherence in osteoporosis patients in Japan. Journal of Bone and Mineral Metabolism 33:1, pages 55-60.
Crossref
Crossref
Inna Dabisch, Jürgen Dethling, Charalabos-Markos Dintsios, Melanie Drechsler, Daniel Kalanovic, Peter Kaskel, Frank Langer, Jörg Ruof, Thorsten Ruppert & Daniel Wirth. (2014) Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany. Health Economics Review 4:1.
Crossref
Crossref
Deepak S. Panmand, Anand D. Tiwari, Siva S. Panda, Jean-Christophe M. Monbaliu, Lucas K. Beagle, Abdullah M. Asiri, Christian V. Stevens, Peter J. Steel, C. Dennis Hall & Alan R. Katritzky. (2014) New benzotriazole-based reagents for the phosphonylation of various N-, O-, and S-nucleophiles. Tetrahedron Letters 55:43, pages 5898-5901.
Crossref
Crossref
Hiroshi Hagino, Hideaki Kishimoto, Hiroaki Ohishi, Sayako Horii & Toshitaka Nakamura. (2014) Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: A comparison with a 2.5mg once-daily dosage regimen. Bone 59, pages 44-52.
Crossref
Crossref
David L. Kendler, David Macarios, Michael J. Lillestol, Alfred Moffett, Sacha Satram-Hoang, Joice Huang, Primal Kaur, En-Tzu Tang, Rachel B. Wagman & Rob Horne. (2014) Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. Menopause 21:1, pages 25-32.
Crossref
Crossref
N G Mokrysheva & L Ya Rozhinskaya. (2013) MODERN VIEW ON THE EFFECTIVENESS OF THERAPY FOR POSTMENOPAUSAL OSTEOPOROSIS. INNOVATIVE DRUGS OF TARGETED ACTION. Osteoporosis and Bone Diseases 16:1, pages 29-33.
Crossref
Crossref
Deborah T. Gold. 2013. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
448
454
.
Jean-Yves Reginster & Olivier BruyèreChristopher R HolroydDarshan JagannathCyrus CooperNicholas C Harvey. 2013. Osteoporosis. Osteoporosis
56
69
.
Jin Woo Park, Seung Rim Hwang, Ok-Cheol Jeon, Hyun Tae Moon & Youngro Byun. (2013) Enhanced Oral Absorption of Ibandronate via Complex Formation with Bile Acid Derivative. Journal of Pharmaceutical Sciences 102:2, pages 341-346.
Crossref
Crossref
Yesim Gokce Kutsal, Nurten Eskiyurt, Jale Irdesel, Vesile Sepici, Hatice Ugurlu, Yesim Kirazli, Fusun Ardic, Mirko Korsic, Tonko Vlak, Mane Grlickov, Snezana Markovic Temelkova, Miroslav Lazarov, Nada Pilipovic, Vera Popovic, Aleksandar Dimic, Branka Kovacev, Dorina Ruci, Argjend Tafaj, Elma Kucukalic-Selimovic, Dijana Avdic, Hajrija Seleskovic, Snjezana Pejicic, Bulent Butun, Gulseren Akyuz, Lale Cerrahoglu, Omer Faruk Sendur, Peyman Yalcin, Sema Oncel, Merih Saridogan, Tunay Sarpel, Mehmet Tosun, Kazim Senel, Savas Gursoy, Ferhan Canturk, Huseyin Demir, Blazenka Miskic, Dalibor Krpan, Franjo Skreb, Simeon Grazio, Zeljka Crncevic-Orlic, Fatih Ozdener & Hakan Oncel. (2013) A candidate identification questionnaire for postmenopausal osteoporosis patients switched from daily or weekly bisphosphonate to once-monthly ibandronate: An open, prospective, multicenter study—BONCURE study. Health 05:07, pages 30-40.
Crossref
Crossref
Deborah T. Gold. 2013. Osteoporosis. Osteoporosis
1909
1921
.
Dima L. Diab, Nelson B. Watts & Paul D. Miller. 2013. Osteoporosis. Osteoporosis
1859
1872
.
Michael R. McClung, Claude-Laurent Benhamou, Zulema Man, Witold Tlustochowicz, Jose R. Zanchetta, Rachelle Eusebio, Ana M. Balske, Ellen Matzkin, Wojciech P. Olszynski, Robert Recker & Pierre D. Delmas. (2012) A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data. Calcified Tissue International 92:1, pages 59-67.
Crossref
Crossref
P. Hadji, V. Ziller, D. Gamerdinger, W. Spieler, K. Articus, M. Baier, R. Moericke & P. H. Kann. (2011) Quality of life and health status with zoledronic acid and generic alendronate—a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporosis International 23:7, pages 2043-2051.
Crossref
Crossref
G. Bianchi, E. Czerwinski, A. Kenwright, A. Burdeska, R. R. Recker & D. Felsenberg. (2011) Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporosis International 23:6, pages 1769-1778.
Crossref
Crossref
Ki Won Oh, Deog-Yoon Kim, Yil-Seob Lee & Moo Il Kang. (2011) Osteoporosis Patient Treatment Satisfaction Questionnaire in postmenopausal women intermittently treated with oral bisphosphonates: the BRAVO study. Journal of Bone and Mineral Metabolism 30:3, pages 359-366.
Crossref
Crossref
E. Barrett-Connor, S. W. Wade, T. P. Do, S. Satram-Hoang, R. Stewart, G. Gao & D. Macarios. (2011) Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™. Osteoporosis International 23:2, pages 733-741.
Crossref
Crossref
Deborah T. Gold, Rob Horne, Cheryl D. Coon, Mark A. Price, Jeff Borenstein, Sepideh F. Varon, Sacha Satram-Hoang & David Macarios. (2011) Development, Reliability, and Validity of a New Preference and Satisfaction Questionnaire. Value in Health 14:8, pages 1109-1116.
Crossref
Crossref
Tonko Vlak, Darko Kaštelan, Petar Lozo, Jure Aljinović, Marina Gradišer, Šime Mijić, Tatjana Nikolić, Blaženka Miškić, Dolores Car, Gordana Tajšić, Tina Dušek, Zrinka Jajić, Frane Grubišić, Tamara Poljičanin, Miro Bakula, Feđa Džubur, Matilda Strižak-Ujević, Mira Kadojić, Maja Radman, Maja Vugrinec, Željka Kuster, Marijeta Pekez, Endi Radović, Ljubica Labar, Željka Crnčević-Orlić & Mirko Koršić. (2011) Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia. Clinical Rheumatology 30:12, pages 1549-1554.
Crossref
Crossref
D. L. Kendler, M. R. McClung, N. Freemantle, M. Lillestol, A. H. Moffett, J. Borenstein, S. Satram-Hoang, Y.-C. Yang, P. Kaur, D. Macarios & S. Siddhanti. (2010) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporosis International 22:6, pages 1725-1735.
Crossref
Crossref
Deborah T. Gold. (2011) Understanding Patient Compliance and Persistence with Osteoporosis Therapy. Drugs & Aging 28:4, pages 249-255.
Crossref
Crossref
S. Lee, P. Glendenning & C. A. Inderjeeth. (2010) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporosis International 22:3, pages 741-753.
Crossref
Crossref
Young Ho LeeGwan Gyu Song. (2011) Efficacy and Safety of Monthly 150 mg Oral Ibandronate in Women with Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. The Korean Journal of Internal Medicine 26:3, pages 340.
Crossref
Crossref
David M ReidDavid M Reid. 2011. Handbook of Osteoporosis. Handbook of Osteoporosis
117
131
.
Patrick B Allen, Hannah Lindsay & Tony CK Tham. (2010) How do patients with inflammatory bowel disease want their biological therapy administered?. BMC Gastroenterology 10:1.
Crossref
Crossref
D. L. Kendler, L. Bessette, C. D. Hill, D. T. Gold, R. Horne, S. F. Varon, J. Borenstein, H. Wang, H.-S. Man, R. B. Wagman, S. Siddhanti, D. Macarios & H. G. Bone. (2009) Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporosis International 21:5, pages 837-846.
Crossref
Crossref
Becky A. Briesacher, Susan E. Andrade, Leslie R. Harrold, Hassan Fouayzi & Robert A. Yood. (2010) Adoption of Once-monthly Oral Bisphosphonates and the Impact on Adherence. The American Journal of Medicine 123:3, pages 275-280.
Crossref
Crossref
Nada Vujasinovic-Stupar, Natasa Milic, Ljiljana Petrovic-Rackov, Nenad Prodanovic, Milena Mijailovic-Ivkovic, Zoran Grujic, Stevan Bukovic, Snezana Novkovic, Katarina Pasalic-Simic, Vera Petrovic, Dragan Vukasinovic & Gordana Perunicic. (2010) Efficacy and safety of once monthly ibandronate treatment in patients with reduced bone mineral density: Esther study. Srpski arhiv za celokupno lekarstvo 138:1-2, pages 56-61.
Crossref
Crossref
Nelson B. Watts, Jacques P. Brown & Gary Cline. (2010) Risedronate on 2 Consecutive Days a Month Reduced Vertebral Fracture Risk at 1 Year Compared With Historical Placebo. Journal of Clinical Densitometry 13:1, pages 56-62.
Crossref
Crossref
Yoon-Sok Chung, Sung-Kil Lim, Ho-Yeon Chung, In-Kyu Lee, Il-Hyung Park, Ghi-Su Kim, Yong-Ki Min, Moo-Il Kang, Dong-Jin Chung, Yong-Ki Kim, Woong Hwan Choi, Min Ho Shong, Ji-Hyun Park, Dong-Won Byun, Hyun-Koo Yoon, Chan Soo Shin, Yil-Seob Lee & Nam-Hee Kwon. (2009) Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women. Calcified Tissue International 85:5, pages 389-397.
Crossref
Crossref
THE BonAdASIA STUDY GROUP. (2009) Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women. International Journal of Rheumatic Diseases 12:3, pages 216-224.
Crossref
Crossref
Bart L. Clarke. (2009) New and emerging treatments for osteoporosis. Clinical Endocrinology 71:3, pages 309-321.
Crossref
Crossref
J Payer, D Čierny, Z Killinger, I Šulková, M Behuliak & P Celec. (2009) Preferences of Patients with Post-Menopausal Osteoporosis Treated with Bisphosphonates – the VIVA II Study. Journal of International Medical Research 37:4, pages 1225-1229.
Crossref
Crossref
Amy H Warriner & Jeffrey R Curtis. (2009) Adherence to osteoporosis treatments: room for improvement. Current Opinion in Rheumatology 21:4, pages 356-362.
Crossref
Crossref
Sydney Lou BonnickStuart SilvermanS. Bobo TannerMark MartensGloria BachmannJoseph D. KohlesRoberto Civitelli. (2009) Patient Satisfaction in Postmenopausal Women Treated with a Weekly Bisphosphonate Transitioned to Once-Monthly Ibandronate. Journal of Women's Health 18:7, pages 935-943.
Crossref
Crossref
Yange Huang, Florian Berthiol, Bart Stegink, Michael M. Pollard & Adriaan J. Minnaard. (2009) Asymmetric Hydrogenation of α,β-Unsaturated Ester- Phosphonates. Advanced Synthesis & Catalysis 351:9, pages 1423-1430.
Crossref
Crossref
William A Blumentals, Steven T Harris, Raymond E Cole, Liping Huang & Stuart L Silverman. (2009) Risk of Severe Gastrointestinal Events in Women Treated with Monthly Ibandronate or Weekly Alendronate and Risedronate. Annals of Pharmacotherapy 43:4, pages 577-585.
Crossref
Crossref
Ronald Emkey, Pierre D. Delmas, Michael Bolognese, Joao Lindolfo C. Borges, Felicia Cosman, Sergio Ragi-Eis, Christopher Recknor, Cristiano A. Zerbini, Colin Neate, Farhad Sedarati & Solomon Epstein. (2009) Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study. Clinical Therapeutics 31:4, pages 751-761.
Crossref
Crossref
Darko Kastelan, Petar Lozo, Doris Stamenkovic, Blazenka Miskic, Tonko Vlak, Zeljka Kolak, Jasminka Milas Ahic, Velimir Altabas, Zeljka Crncevic Orlic & Mirko Korsic. (2008) Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. Clinical Rheumatology 28:3, pages 321-326.
Crossref
Crossref
Jean-Yves ReginsterMickaël HiligsmannVéronique RabendaBrigitte ZegelsAudrey NeuprezOlivier Bruyere. (2009) Ibandronate in the Management of Postmenopausal Osteoporosis. Clinical Medicine. Therapeutics 1, pages CMT.S2354.
Crossref
Crossref
M. Sosa Henríquez & M.J. Gómez de Tejada Romero. (2009) La medicina basada en la evidencia y los fármacos aprobados para el tratamiento de la osteoporosis. Papel del calcio y la vitamina D. Revista Clínica Española 209:1, pages 25-36.
Crossref
Crossref
Deborah T. Gold, Sydney Lou Bonnick, Mayur M. Amonkar, Hosam K. Kamel, Shuchita Agarwal & Mone Zaidi. (2008) Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy. Gender Medicine 5:4, pages 374-384.
Crossref
Crossref
Darko Kastelan, Mirko Korsic & Tonko Vlak. (2008) Ibandronate: is there an effect on nonvertebral fractures?. Clinical Rheumatology 27:10, pages 1313-1315.
Crossref
Crossref
Mark G. Martens & Howard Shaw. (2008) Maximizing Effectiveness of Bisphosphonate Therapy for Osteoporosis. Southern Medical Journal 101:8, pages 824-830.
Crossref
Crossref
Yuzaburo Inoue, Naoki Shimojo, Shuichi Suzuki, Takayasu Arima, Minako Tomiita, Masanori Minagawa & Yoichi Kohno. (2008) Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. Clinical Rheumatology 27:7, pages 909-912.
Crossref
Crossref
S E Papapoulos & R C Schimmer. (2008) Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Postgraduate Medical Journal 84:992, pages 307-312.
Crossref
Crossref
Patrick G Clay, Laura E Voss, Charlott Williams & Eric C Daume. (2008) Valid Treatment Options for Osteoporosis and Osteopenia in HIV-Infected Persons. Annals of Pharmacotherapy 42:5, pages 670-679.
Crossref
Crossref
Peyman Hadji, Helmut Minne, Michael Pfeifer, Pierre Bourgeois, Patrice Fardellone, Angelo A Licata, Vipul Devas, Daiva Masanauskaite & Elizabeth Barrett-Connor. (2008) Étude de la préférence des patientes ménopausées ostéoporotiques pour l’ibandronate oral mensuel ou pour l’alendronate oral hebdomadaire : étude randomisée en cross-over (BALTO II). Revue du Rhumatisme 75:5, pages 438-446.
Crossref
Crossref
Peyman Hadji, Helmut Minne, Michael Pfeifer, Pierre Bourgeois, Patrice Fardellone, Angelo Licata, Vipul Devas, Daiva Masanauskaite & Elizabeth Barrett-Connor. (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine 75:3, pages 303-310.
Crossref
Crossref
Mauro Bianchi, Silvia Franchi, Paolo Ferrario, Maria Luisa Sotgiu & Paola Sacerdote. (2008) Effects of the bisphosphonate ibandronate on hyperalgesia, substance P, and cytokine levels in a rat model of persistent inflammatory pain. European Journal of Pain 12:3, pages 284-292.
Crossref
Crossref
F. J. A. Penning-van Beest, J. A. Erkens, M. Olson & R. M. C. Herings. (2007) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporosis International 19:4, pages 511-517.
Crossref
Crossref
François-Emery Cotté, Bernard Cortet, Antoine Lafuma, Bernard Avouac, Abdelkader El Hasnaoui, Patrice Fardellone, Denis Pouchain, Christian Roux & Anne-Françoise Gaudin. (2008) Modélisation de l’impact de santé publique d’une meilleure persistance au traitement de l’ostéoporose post-ménopausique en France. Revue du Rhumatisme 75:3, pages 280-288.
Crossref
Crossref
François-Emery Cotté, Bernard Cortet, Antoine Lafuma, Bernard Avouac, Abdelkader El Hasnaoui, Patrice Fardellone, Denis Pouchain, Christian Roux & Anne-Françoise Gaudin. (2008) A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. Joint Bone Spine 75:2, pages 201-208.
Crossref
Crossref
Juraj Payer, Zdenko Killinger, Ivana Šulková & Peter Celec. (2008) Preferences of patients receiving bisphosphonates – How to influence the therapeutic adherence. Biomedicine & Pharmacotherapy 62:2, pages 122-124.
Crossref
Crossref
James E Frampton & Caroline M Perry. (2008) Ibandronate. Drugs 68:18, pages 2683-2707.
Crossref
Crossref
PAUL D. MILLER. 2008. Osteoporosis. Osteoporosis
1725
1742
.
DEBORAH T. GOLD & SAMANTHA SOLIMEO. 2008. Osteoporosis. Osteoporosis
1547
1553
.
Deborah T Gold & Stuart L Silverman. (2007) Compliance and persistence with osteoporosis therapies: we can do better. Future Rheumatology 2:5, pages 443-445.
Crossref
Crossref
Thomas W. Weiss & Colleen A. McHorney. (2007) Osteoporosis medication profile preference: results from the PREFER-US study. Health Expectations 10:3, pages 211-223.
Crossref
Crossref
Hosam K. Kamel. (2007) Update on Osteoporosis Management in Long-term Care: Focus on Bisphosphonates. Journal of the American Medical Directors Association 8:7, pages 434-440.
Crossref
Crossref
Stuart L. Silverman & Michael Maricic. (2007) Recent Developments in Bisphosphonate Therapy. Seminars in Arthritis and Rheumatism 37:1, pages 1-12.
Crossref
Crossref
Felicia Cosman, Joao L.C. Borges & Manuel Diaz Curiel. (2007) Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: The role of comparative studies and implications for future studies. Clinical Therapeutics 29:6, pages 1116-1127.
Crossref
Crossref
Juraj Payer, Zdenko Killinger, Ivana Šulková & Peter Celec. (2007) Therapeutic adherence to bisphosphonates. Biomedicine & Pharmacotherapy 61:4, pages 191-193.
Crossref
Crossref
E. Nieto-Andueza. (2007) Nueva dosificación de un bifosfonato para la prevención y el tratamiento de la osteoporosis posmenopáusica. Revista Española de Enfermedades Metabólicas Óseas 16:3, pages 58-61.
Crossref
Crossref
E. Seeman, J. Compston, J. Adachi, M. L. Brandi, C. Cooper, B. Dawson-Hughes, B. Jönsson, H. Pols & J. A. Cramer. (2007) Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporosis International 18:6, pages 711-719.
Crossref
Crossref
- -. (2007) Novyy etap v sovremennoy terapiipostmenopauzal'nogo osteoporoza. Obesity and metabolism 4:1, pages 47-48.
Crossref
Crossref
Hom‐Lay Wang, Daniel Weber & Laurie K. McCauley. (2007) Effect of Long‐Term Oral Bisphosphonates on Implant Wound Healing: Literature Review and a Case Report. Journal of Periodontology 78:3, pages 584-594.
Crossref
Crossref
Jesús Walliser Duarte, Susan C. Bolge & Shuvayu S. Sen. (2007) An Evaluation of patients' preferences for osteoporosis medications and their attributes: The PREFER-international study. Clinical Therapeutics 29:3, pages 488-503.
Crossref
Crossref
Jean-Yves Reginster, Olivier Malaise, Audrey Neuprez, Victor-Emmanuel Jouret & Pierre Close. (2007) Intermittent Bisphosphonate Therapy in Postmenopausal Osteoporosis. Drugs & Aging 24:5, pages 351-359.
Crossref
Crossref
Reiner Bartl, Bertha Frisch, Emmo von Tresckow & Christoph Bartl. 2007. Bisphosphonates in Medical Practice. Bisphosphonates in Medical Practice
235
258
.
Joyce A. Cramer, Niall O. Lynch, Anne-Francoise Gaudin, Mel Walker & Warren Cowell. (2006) The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France. Clinical Therapeutics 28:10, pages 1686-1694.
Crossref
Crossref
Ethel S. Siris, Steven T. Harris, Clifford J. Rosen, Charles E. Barr, James N. Arvesen, Thomas A. Abbott & Stuart Silverman. (2006) Adherence to Bisphosphonate Therapy and Fracture Rates in Osteoporotic Women: Relationship to Vertebral and Nonvertebral Fractures From 2 US Claims Databases. Mayo Clinic Proceedings 81:8, pages 1013-1022.
Crossref
Crossref
A. COOPER, J. DRAKE & E. BRANKIN. (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study*. International Journal of Clinical Practice 60:8, pages 896-905.
Crossref
Crossref
Sumapa Chaiamnuay & Kenneth G. Saag. (2006) Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?. Reviews in Endocrine and Metabolic Disorders 7:1-2, pages 101-112.
Crossref
Crossref
Ronald Emkey. (2016) Ibandronate: Once-Monthly and Intravenous Dosing Options for Osteoporosis Treatment. Women's Health 2:3, pages 341-349.
Crossref
Crossref
Eunice Y. Pyon. (2006) Once-monthly Ibandronate for postmenopausal Osteoporosis: Review of a new dosing regimen. Clinical Therapeutics 28:4, pages 475-490.
Crossref
Crossref